NO873184L - Polymer behandlede jone bytte harpiks. - Google Patents

Polymer behandlede jone bytte harpiks.

Info

Publication number: NO873184L
Authority: NO; Norway
Prior art keywords: resin; particles; complex; polymer; coated
Prior art date: 1986-07-30

Application number

NO873184A

Other languages

English (en)

Norwegian (no)

Other versions

NO873184D0 (no

Inventor

San-Laung Chow

Yegnaswami Raghunathan

Original Assignee

Pennwalt Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-30

Filing date

1987-07-29

Publication date

1988-02-01

1987-07-29 Application filed by Pennwalt Corp filed Critical Pennwalt Corp

1987-07-29 Publication of NO873184D0 publication Critical patent/NO873184D0/no

1988-02-01 Publication of NO873184L publication Critical patent/NO873184L/no

Links

239000011347 resin Substances 0.000 title claims description 50
229920005989 resin Polymers 0.000 title claims description 50
229920000642 polymer Polymers 0.000 title claims description 11
239000002245 particle Substances 0.000 claims description 38
239000003814 drug Substances 0.000 claims description 25
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 8
230000004888 barrier function Effects 0.000 claims description 7
238000009792 diffusion process Methods 0.000 claims description 7
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
239000003729 cation exchange resin Substances 0.000 claims description 5
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 4
239000000770 propane-1,2-diol alginate Substances 0.000 claims description 4
235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 4
239000000230 xanthan gum Substances 0.000 claims description 4
235000010493 xanthan gum Nutrition 0.000 claims description 4
229920001285 xanthan gum Polymers 0.000 claims description 4
229940082509 xanthan gum Drugs 0.000 claims description 4
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
229940096529 carboxypolymethylene Drugs 0.000 claims description 3
229920006158 high molecular weight polymer Polymers 0.000 claims description 3
238000000576 coating method Methods 0.000 description 23
239000011248 coating agent Substances 0.000 description 20
229940079593 drug Drugs 0.000 description 15
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 14
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 14
229960000395 phenylpropanolamine Drugs 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229920001429 chelating resin Polymers 0.000 description 5
239000001856 Ethyl cellulose Substances 0.000 description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
235000019325 ethyl cellulose Nutrition 0.000 description 4
229920001249 ethyl cellulose Polymers 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000003456 ion exchange resin Substances 0.000 description 4
229920003303 ion-exchange polymer Polymers 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000010668 complexation reaction Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
238000010828 elution Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
-1 hydocodone Chemical compound 0.000 description 2
239000007788 liquid Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000563 toxic property Toxicity 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
QWFMDSOYEQHWMF-UHFFFAOYSA-N 2,3-bis(ethenyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(C=C)=C1C=C QWFMDSOYEQHWMF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/20—Manufacture of shaped structures of ion-exchange resins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Manufacturing & Machinery (AREA)
Chemical Kinetics & Catalysis (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Chemically Coating (AREA)
Treatments Of Macromolecular Shaped Articles (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO873184A 1986-07-30 1987-07-29 Polymer behandlede jone bytte harpiks. NO873184L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89216886A	1986-07-30	1986-07-30

Publications (2)

Publication Number	Publication Date
NO873184D0 NO873184D0 (no)	1987-07-29
NO873184L true NO873184L (no)	1988-02-01

Family

ID=25399485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873184A NO873184L (no)	1986-07-30	1987-07-29	Polymer behandlede jone bytte harpiks.

Country Status (12)

Country	Link
EP (1)	EP0254822A3 (da)
JP (1)	JP2670776B2 (da)
KR (1)	KR880001732A (da)
AU (1)	AU7242287A (da)
CA (1)	CA1283497C (da)
DK (1)	DK394887A (da)
FI (1)	FI872581A7 (da)
IL (1)	IL82426A0 (da)
NO (1)	NO873184L (da)
NZ (1)	NZ219925A (da)
PH (1)	PH23585A (da)
ZA (1)	ZA873016B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4911920A (en) *	1986-07-30	1990-03-27	Alcon Laboratories, Inc.	Sustained release, comfort formulation for glaucoma therapy
IE62100B1 (en) *	1986-07-30	1994-12-14	Fisons Corp	Coated ion exchange resins
US4996047A (en) *	1988-11-02	1991-02-26	Richardson-Vicks, Inc.	Sustained release drug-resin complexes
US4999189A (en) *	1988-11-14	1991-03-12	Schering Corporation	Sustained release oral suspensions
US5186930A (en) *	1988-11-14	1993-02-16	Schering Corporation	Sustained release oral suspensions
US5296228A (en) *	1992-03-13	1994-03-22	Allergan, Inc.	Compositions for controlled delivery of pharmaceutical compounds
KR100440544B1 (ko) *	1998-07-31	2004-07-15	니켄 가가쿠 가부시키가이샤	양이온 교환수지 제제
JP4808405B2 (ja)	2002-11-26	2011-11-02	ホ−レンベックギャリ− ア−ル	高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム
CN1845722A (zh) *	2003-09-03	2006-10-11	马林克罗特公司	粒状缓释制剂及其生产
EP2508174A1 (en)	2011-04-06	2012-10-10	Ljiljana Sovic Brkicic	Pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB982150A (en) *	1961-09-29	1965-02-03	Glaxo Group Ltd	Therapeutic resin complexes
US3594470A (en) *	1968-02-19	1971-07-20	Abbott Lab	Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
US4221778A (en) *	1979-01-08	1980-09-09	Pennwalt Corporation	Prolonged release pharmaceutical preparations
CA1236023A (en) *	1984-07-18	1988-05-03	Yegnaswami Raghunathan	Controlled release pharmaceutical preparations

1987
- 1987-04-08 NZ NZ219925A patent/NZ219925A/xx unknown
- 1987-04-27 PH PH35183A patent/PH23585A/en unknown
- 1987-04-27 CA CA000535699A patent/CA1283497C/en not_active Expired - Fee Related
- 1987-04-28 ZA ZA873016A patent/ZA873016B/xx unknown
- 1987-05-01 AU AU72422/87A patent/AU7242287A/en not_active Abandoned
- 1987-05-05 EP EP87106496A patent/EP0254822A3/en not_active Ceased
- 1987-05-05 IL IL82426A patent/IL82426A0/xx unknown
- 1987-06-09 FI FI872581A patent/FI872581A7/fi not_active IP Right Cessation
- 1987-07-28 JP JP62186780A patent/JP2670776B2/ja not_active Expired - Fee Related
- 1987-07-29 NO NO873184A patent/NO873184L/no unknown
- 1987-07-29 KR KR1019870008227A patent/KR880001732A/ko not_active Withdrawn
- 1987-07-29 DK DK394887A patent/DK394887A/da unknown

Also Published As

Publication number	Publication date
ZA873016B (en)	1988-02-24
DK394887D0 (da)	1987-07-29
NO873184D0 (no)	1987-07-29
EP0254822A2 (en)	1988-02-03
FI872581A0 (fi)	1987-06-09
JPS6335526A (ja)	1988-02-16
EP0254822A3 (en)	1989-04-05
FI872581L (fi)	1988-01-31
IL82426A0 (en)	1987-11-30
PH23585A (en)	1989-09-11
CA1283497C (en)	1991-04-23
NZ219925A (en)	1989-06-28
DK394887A (da)	1988-01-31
FI872581A7 (fi)	1988-01-31
JP2670776B2 (ja)	1997-10-29
AU7242287A (en)	1988-02-04
KR880001732A (ko)	1988-04-26

Publication	Publication Date	Title
US4859461A (en)	1989-08-22	Coatable ion exchange resins
US4847077A (en)	1989-07-11	Controlled release pharmaceutical preparations
US4959219A (en)	1990-09-25	Coating barriers comprising ethyl cellulose
US4221778A (en)	1980-09-09	Prolonged release pharmaceutical preparations
Raghunathan et al.	1981	Sustained‐release drug delivery system I: Coated ion‐exchange resin system for phenylpropanolamine and other drugs
Guo et al.	2009	Ion-exchange resins as drug delivery carriers
KR950003609B1 (ko)	1995-04-17	지속적 방출성의 제약학적 제제의 제조방법
US4859462A (en)	1989-08-22	Polymer-treated ion exchange resins
EP0254811B1 (en)	1993-08-18	Coated ion exchange resins
NO852880L (no)	1986-01-20	Fremgangsmaate ved fremstilling av farmasoeytisk preparat med forsinket frigjoering
DK160601B (da)	1991-04-02	Farmaceutisk harpiksholdigt, sustained release praeparat med kontrolleret afgivelse af et farmaceutisk acceptabelt syreadditionssalt af dextromethorphan samt fremgangsmaade til fremstilling deraf
JP2012176992A (ja)	2012-09-13	架橋シェルを有するコア−シェルコンポジットを製造する方法および該方法によって生じたコア−シェルコンポジット
JP2009510126A (ja)	2009-03-12	哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
NO873184L (no)	1988-02-01	Polymer behandlede jone bytte harpiks.
AU663695B2 (en)	1995-10-19	Polyamine drug-resin complexes
JPH02250822A (ja)	1990-10-08	中空顆粒状医薬及びその製法
FI65910C (fi)	1984-08-10	Foerfarande foer framstaellning av farmaceutiska preparat med laongtidsverkan
Lee et al.	1998	Preparation and characterization of melatonin-loaded stearyl alcohol microspheres
GB2220142A (en)	1990-01-04	Process for the film-coating of pharmaceutical compositions with polymer dispersions
EP3727340A1 (en)	2020-10-28	Pharmaceutical composition containing crosslinked ion exchange resin
JPH07112928A (ja)	1995-05-02	難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
Matthew	2016	Microencapsulated Garcinia kola and Hunteria umbellata Seeds Aqueous Extracts-Part 2: Influence of Some Selected Pharmaceutical Excipients
Sriwongjanya	1996	Pharmaceutical applications of ion exchange resins
Rathod Utsav et al.	0	INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
WO2019126321A1 (en)	2019-06-27	Pharmaceutical composition containing resin particles